Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

収録刊行物

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ